Keyphrases
Early Onset
100%
Endocrine Therapy
100%
Estrogen Receptor 1 (ESR1)
100%
Exemestane
100%
Cytochrome P450 19A1
100%
Single nucleotide Polymorphism
57%
Sweating
57%
Hot Flashes
57%
Odds Ratio
42%
Adverse Events
28%
Postmenopausal Women
28%
Early Breast Cancer
28%
Premenopausal Patients
28%
Germ Cells
14%
Genetic Variants
14%
Trial Registration
14%
Genotype
14%
Breast Cancer Risk
14%
Clinical Impact
14%
Logistic Regression Model
14%
First Year
14%
Polymorphism
14%
Low Incidence
14%
Musculoskeletal Symptoms
14%
Hormone-responsive
14%
Treatment Efficacy
14%
Treatment Adherence
14%
Translational Studies
14%
Intention-to-treat
14%
Therapy Response
14%
Patients with Breast Cancer
14%
Mediating Effect
14%
Musculoskeletal Adverse Event
14%
QIAamp
14%
Ovarian Suppression
14%
Pyrosequencing Technique
14%
Rs9340799
14%
Rs2234693
14%
Medicine and Dentistry
Hormone Therapy
100%
Tamoxifen
100%
Side Effect
100%
Aromatase
100%
Estrogen Receptor Alpha
100%
Exemestane
100%
Single Nucleotide Polymorphism
57%
Breast Cancer
57%
Hot Flush
57%
Adverse Event
42%
Odds Ratio
42%
Treatment Response
14%
Combination Therapy
14%
Cancer Risk
14%
Postmenopause
14%
Patient Compliance
14%
Logistic Regression Analysis
14%
Intention-to-Treat Analysis
14%
Musculoskeletal Disease
14%
Premenopause
14%
Pyrosequencing
14%
Sweating
14%
Germ Cell
14%
Biochemistry, Genetics and Molecular Biology
Estrogen Receptor Alpha
100%
Aromatase
100%
Exemestane
100%
Single-Nucleotide Polymorphism
57%
Flushing
57%
Germline
14%
Germ Cell
14%
Postmenopause
14%
Premenopause
14%
Genotyping
14%
Patient Compliance
14%
Pyrosequencing
14%
Sweating
14%
Immunology and Microbiology
Cytochrome P450
100%
Single Nucleotide Polymorphism
57%
Flushing
57%
Premenopause
14%
Postmenopause
14%
Pyrosequencing
14%
Sweating
14%
Germ Cell
14%